{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:03:01Z","timestamp":1791219781514,"version":"4.1.0"},"reference-count":8,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T00:00:00Z","timestamp":1771113600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T00:00:00Z","timestamp":1771113600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2026,5]]},"abstract":"ABSTRACT<\/jats:title>\n \n Background<\/jats:title>\n Secondary prophylaxis following treatment of CMV infection in solid organ transplant recipients (SOTRs) may be considered in high\u2010risk SOTRs, although utilization criteria are not well described. The addition of CMV\u2010specific T\u2010cell immunity assay testing may help guide selection of SOTRs for secondary prophylaxis.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n All SOTRs at a single center with CMV T\u2010cell assays obtained during secondary prophylaxis between January 2020 and August 2023 were reviewed. CMV antiviral secondary prophylaxis discontinuation rates and subsequent need for antiviral therapy re\u2010initiation were recorded. Positive predictive and negative predictive values of the assay, as well as the association between absolute lymphocyte count (ALC) and CMV T cell assay variables, were assessed.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n CMV T\u2010cell assay results in 32\/78 (41%) SOTRs showed adequate response. Secondary prophylaxis was discontinued in 27 (84.4%) with adequate and 13 (28.2%) with inadequate T\u2010cell response (\n p<\/jats:italic>\n \u00a0<\u00a00.005). CMV DNAemia requiring re\u2010initiation of CMV therapy occurred in 2\/27 (7.4%) of the adequate and 3\/13 (23.1%) of the inadequate response cohorts (\n p<\/jats:italic>\n \u00a0=\u00a00.056), demonstrating a PPV and NPV of 92.6% and 23.1%, respectively, with 71.4% sensitivity and 60% specificity. When combined with ALC >\u00a00.5 10\n 9<\/jats:sup>\n \/L at time of assay, an adequate T cell assay response was significantly associated with no CMV reactivation (\n n<\/jats:italic>\n \u00a0=\u00a00\/22,\n p<\/jats:italic>\n \u00a0<\u00a00.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n In this exploratory population, the combination of an adequate CMV T\u2010cell assay with adequate ALC was strongly predictive of no CMV reactivation. Further investigation into the predictive characteristics of a CMV T\u2010cell assay combined with ALC and other patient\u2010specific factors may optimize its clinical application.\n \n \n image<\/jats:alt-text>\n <\/jats:graphic>\n <\/jats:boxed-text>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/tid.70185","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T07:28:54Z","timestamp":1771226934000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Utilization of a CMV T Cell Immunity Assay to Guide Secondary Prophylaxis in Solid Organ Transplant Recipients"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6688-8573","authenticated-orcid":false,"given":"Christina","family":"Doligalski","sequence":"first","affiliation":[{"name":"Department of Pharmacy UNC Health Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7596-4272","authenticated-orcid":false,"given":"Luther","family":"Bartelt","sequence":"additional","affiliation":[{"name":"Department of Medicine UNC Chapel Hill School of Medicine Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5229-6438","authenticated-orcid":false,"given":"Anne M.","family":"Lachiewicz","sequence":"additional","affiliation":[{"name":"Department of Medicine UNC Chapel Hill School of Medicine Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1206-2175","authenticated-orcid":false,"given":"Arlene C.","family":"Se\u00f1a","sequence":"additional","affiliation":[{"name":"Department of Medicine UNC Chapel Hill School of Medicine Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4309-7896","authenticated-orcid":false,"given":"Mary","family":"Chandran","sequence":"additional","affiliation":[{"name":"Department of Pharmacy UNC Health Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,15]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000005374"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13512"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1086\/342601"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix696"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1209"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/10600280231207899"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab574"},{"key":"e_1_2_9_9_1","unstructured":"\u201cCMV inSIGHT\u2122 T Cell Immunity Testing \u201dEurofins Viracor accessed November 11 2024 https:\/\/www.eurofins\u2010viracor.com\/clinical\/test\u2010menu\/30360\u2010cmv\u2010insight\u2010t\u2010cell\u2010immunity\/."}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.70185","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/tid.70185","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.70185","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:56:34Z","timestamp":1789206994000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.70185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,15]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1111\/tid.70185"],"URL":"https:\/\/doi.org\/10.1111\/tid.70185","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,15]]},"assertion":[{"value":"2025-09-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70185"}}